title: Topical 1% 5-fluorouracil in ocular surface squamous neoplasia: a long-term safety study.
abstract: OBJECTIVE
  The aim of this study was to evaluate the long-term corneal toxicity of topical chemotherapy with 1% 5-fluorouracil (5-FU) as a sole or adjuvant treatment of ocular surface squamous neoplasia (OSSN).
  
  
  METHODS
  Forty-one consecutive cases of OSSN were included in this prospective study. Patients underwent topical chemotherapy with 1% 5-FU four times/day for 4&emsp14;weeks (one course). Adjunctive courses were repeated until clinical and cytological tumour regression. Clinical confocal microscopy was used to check for 5-FU long-term corneal toxicity.
  
  
  RESULTS
  Mean follow-up was 89.7±14.4&emsp14;months (range 63-122&emsp14;months). Twenty-two patients (53.7%) underwent topical 5-FU as a sole treatment, and 19 patients (46.3%) as adjuvant and/or debulking therapy. The mean number of 5-FU cycles was 1.9 (range 1-5 cycles). Three tumours (7.3%) treated with 5-FU alone recurred during follow-up. Recurrences were successfully treated with additional 5-FU courses. Clinical confocal microscopy showed no long-term difference between the treated eye and fellow (control) eye in: endothelial cells count, pleomorphism and polymegatism, anterior stromal keratocyte density, sub-basal nerve plexus fibre number, density, and beadings and central cornea epithelium thickness (p=NS).
  
  
  CONCLUSIONS
  Topical 5-FU, as a sole or combined therapy, must be considered a long-term safe and effective treatment for patients affected by OSSN.
authors.affiliation: Department of Ophthalmology, University of Padua, Via Giustiniani 2, Padua 35128, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Parrozzani
authors.forename: Daniela
authors.initials: D
authors.lastname: Lazzarini
authors.forename: Ernesto
authors.initials: E
authors.lastname: Alemany-Rubio
authors.forename: Francesca
authors.initials: F
authors.lastname: Urban
authors.forename: Edoardo
authors.initials: E
authors.lastname: Midena
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D018613:Microscopy, Confocal; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D005472:Fluorouracil